Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379

from discovery to a randomized, double-blind, placebo-controlled trial

Hironori Nakagami, Ken Sugimoto, Takahiro Ishikawa, Taku Fujimoto, Toshifumi Yamaoka, Misa Hayashi, Eiji Kiyohara, Hiroshi Ando, Yuta Terabe, Yoichi Takami, Koichi Yamamoto, Yasushi Takeya, Minoru Takemoto, Masaya Koshizaka, Tamotsu Ebihara, Ayumi Nakamura, Mitsunori Nishikawa, Xiang Jing Yao, Hideki Hanaoka, Ichiro Katayama & 2 others Koutaro Yokote, Hiromi Rakugi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

SR-0379 is a functional peptide that has wound healing effect with anti-microbial action, making it an ideal drug to prevent infection. To evaluate the safety, efficacy, and pharmacokinetics of SR-0379 for the treatment of leg ulcers, a physician-initiated, phase I/IIa, first-in-patient clinical study was designed. A multi-center, double-blind, randomized clinical study was conducted from October 2015 to September 2016. The inclusion criteria for leg ulcers were (1) diabetes or critical limb ischemia and (2) wound size <6 cm in diameter. Twelve patients were randomized into four groups and administered 0.02%, 0.1%, or 0.5% SR-0379 or placebo treatment on skin ulcers once per day for 28 days. Efficiency was evaluated by determining the rate of wound size reduction as a primary endpoint at 4 weeks after the first treatment compared with the pre-treatment wound size. As a secondary endpoint, the DESIGN-R score index, time to wound closure, and the 50% wound size reduction ratio were also evaluated. The safety of SR-0379 was evaluated during the study period. In the evaluation of efficiency, the skin ulcer reduction rates at the last evaluation were 44.73% for the 0.02% SR-0379 group, 68.25% for the 0.1% group, and 71.61% for the 0.5% group, compared with 9.95% for the placebo group. Six adverse events were reported in four patients, of which one occurred in the placebo group, and causal relationships to study drugs were denied for all six events. Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective.

Original languageEnglish
Article number2
Journalnpj Aging and Mechanisms of Disease
Volume4
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Ulcer
Extremities
Placebos
Physicians
Peptides
Leg Ulcer
Skin Ulcer
Wounds and Injuries
Therapeutics
Safety
Pharmaceutical Preparations
Wound Healing
Clinical Studies
SR-0379
Ischemia
Pharmacokinetics
Infection

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Ageing

Cite this

Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379 : from discovery to a randomized, double-blind, placebo-controlled trial. / Nakagami, Hironori; Sugimoto, Ken; Ishikawa, Takahiro; Fujimoto, Taku; Yamaoka, Toshifumi; Hayashi, Misa; Kiyohara, Eiji; Ando, Hiroshi; Terabe, Yuta; Takami, Yoichi; Yamamoto, Koichi; Takeya, Yasushi; Takemoto, Minoru; Koshizaka, Masaya; Ebihara, Tamotsu; Nakamura, Ayumi; Nishikawa, Mitsunori; Yao, Xiang Jing; Hanaoka, Hideki; Katayama, Ichiro; Yokote, Koutaro; Rakugi, Hiromi.

In: npj Aging and Mechanisms of Disease, Vol. 4, No. 1, 2, 01.12.2018.

Research output: Contribution to journalArticle

Nakagami, H, Sugimoto, K, Ishikawa, T, Fujimoto, T, Yamaoka, T, Hayashi, M, Kiyohara, E, Ando, H, Terabe, Y, Takami, Y, Yamamoto, K, Takeya, Y, Takemoto, M, Koshizaka, M, Ebihara, T, Nakamura, A, Nishikawa, M, Yao, XJ, Hanaoka, H, Katayama, I, Yokote, K & Rakugi, H 2018, 'Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial', npj Aging and Mechanisms of Disease, vol. 4, no. 1, 2. https://doi.org/10.1038/s41514-018-0021-7
Nakagami, Hironori ; Sugimoto, Ken ; Ishikawa, Takahiro ; Fujimoto, Taku ; Yamaoka, Toshifumi ; Hayashi, Misa ; Kiyohara, Eiji ; Ando, Hiroshi ; Terabe, Yuta ; Takami, Yoichi ; Yamamoto, Koichi ; Takeya, Yasushi ; Takemoto, Minoru ; Koshizaka, Masaya ; Ebihara, Tamotsu ; Nakamura, Ayumi ; Nishikawa, Mitsunori ; Yao, Xiang Jing ; Hanaoka, Hideki ; Katayama, Ichiro ; Yokote, Koutaro ; Rakugi, Hiromi. / Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379 : from discovery to a randomized, double-blind, placebo-controlled trial. In: npj Aging and Mechanisms of Disease. 2018 ; Vol. 4, No. 1.
@article{b40c23df07524d38ad810df3d224f552,
title = "Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial",
abstract = "SR-0379 is a functional peptide that has wound healing effect with anti-microbial action, making it an ideal drug to prevent infection. To evaluate the safety, efficacy, and pharmacokinetics of SR-0379 for the treatment of leg ulcers, a physician-initiated, phase I/IIa, first-in-patient clinical study was designed. A multi-center, double-blind, randomized clinical study was conducted from October 2015 to September 2016. The inclusion criteria for leg ulcers were (1) diabetes or critical limb ischemia and (2) wound size <6 cm in diameter. Twelve patients were randomized into four groups and administered 0.02{\%}, 0.1{\%}, or 0.5{\%} SR-0379 or placebo treatment on skin ulcers once per day for 28 days. Efficiency was evaluated by determining the rate of wound size reduction as a primary endpoint at 4 weeks after the first treatment compared with the pre-treatment wound size. As a secondary endpoint, the DESIGN-R score index, time to wound closure, and the 50{\%} wound size reduction ratio were also evaluated. The safety of SR-0379 was evaluated during the study period. In the evaluation of efficiency, the skin ulcer reduction rates at the last evaluation were 44.73{\%} for the 0.02{\%} SR-0379 group, 68.25{\%} for the 0.1{\%} group, and 71.61{\%} for the 0.5{\%} group, compared with 9.95{\%} for the placebo group. Six adverse events were reported in four patients, of which one occurred in the placebo group, and causal relationships to study drugs were denied for all six events. Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective.",
author = "Hironori Nakagami and Ken Sugimoto and Takahiro Ishikawa and Taku Fujimoto and Toshifumi Yamaoka and Misa Hayashi and Eiji Kiyohara and Hiroshi Ando and Yuta Terabe and Yoichi Takami and Koichi Yamamoto and Yasushi Takeya and Minoru Takemoto and Masaya Koshizaka and Tamotsu Ebihara and Ayumi Nakamura and Mitsunori Nishikawa and Yao, {Xiang Jing} and Hideki Hanaoka and Ichiro Katayama and Koutaro Yokote and Hiromi Rakugi",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41514-018-0021-7",
language = "English",
volume = "4",
journal = "npj Aging and Mechanisms of Disease",
issn = "2056-3973",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379

T2 - from discovery to a randomized, double-blind, placebo-controlled trial

AU - Nakagami, Hironori

AU - Sugimoto, Ken

AU - Ishikawa, Takahiro

AU - Fujimoto, Taku

AU - Yamaoka, Toshifumi

AU - Hayashi, Misa

AU - Kiyohara, Eiji

AU - Ando, Hiroshi

AU - Terabe, Yuta

AU - Takami, Yoichi

AU - Yamamoto, Koichi

AU - Takeya, Yasushi

AU - Takemoto, Minoru

AU - Koshizaka, Masaya

AU - Ebihara, Tamotsu

AU - Nakamura, Ayumi

AU - Nishikawa, Mitsunori

AU - Yao, Xiang Jing

AU - Hanaoka, Hideki

AU - Katayama, Ichiro

AU - Yokote, Koutaro

AU - Rakugi, Hiromi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - SR-0379 is a functional peptide that has wound healing effect with anti-microbial action, making it an ideal drug to prevent infection. To evaluate the safety, efficacy, and pharmacokinetics of SR-0379 for the treatment of leg ulcers, a physician-initiated, phase I/IIa, first-in-patient clinical study was designed. A multi-center, double-blind, randomized clinical study was conducted from October 2015 to September 2016. The inclusion criteria for leg ulcers were (1) diabetes or critical limb ischemia and (2) wound size <6 cm in diameter. Twelve patients were randomized into four groups and administered 0.02%, 0.1%, or 0.5% SR-0379 or placebo treatment on skin ulcers once per day for 28 days. Efficiency was evaluated by determining the rate of wound size reduction as a primary endpoint at 4 weeks after the first treatment compared with the pre-treatment wound size. As a secondary endpoint, the DESIGN-R score index, time to wound closure, and the 50% wound size reduction ratio were also evaluated. The safety of SR-0379 was evaluated during the study period. In the evaluation of efficiency, the skin ulcer reduction rates at the last evaluation were 44.73% for the 0.02% SR-0379 group, 68.25% for the 0.1% group, and 71.61% for the 0.5% group, compared with 9.95% for the placebo group. Six adverse events were reported in four patients, of which one occurred in the placebo group, and causal relationships to study drugs were denied for all six events. Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective.

AB - SR-0379 is a functional peptide that has wound healing effect with anti-microbial action, making it an ideal drug to prevent infection. To evaluate the safety, efficacy, and pharmacokinetics of SR-0379 for the treatment of leg ulcers, a physician-initiated, phase I/IIa, first-in-patient clinical study was designed. A multi-center, double-blind, randomized clinical study was conducted from October 2015 to September 2016. The inclusion criteria for leg ulcers were (1) diabetes or critical limb ischemia and (2) wound size <6 cm in diameter. Twelve patients were randomized into four groups and administered 0.02%, 0.1%, or 0.5% SR-0379 or placebo treatment on skin ulcers once per day for 28 days. Efficiency was evaluated by determining the rate of wound size reduction as a primary endpoint at 4 weeks after the first treatment compared with the pre-treatment wound size. As a secondary endpoint, the DESIGN-R score index, time to wound closure, and the 50% wound size reduction ratio were also evaluated. The safety of SR-0379 was evaluated during the study period. In the evaluation of efficiency, the skin ulcer reduction rates at the last evaluation were 44.73% for the 0.02% SR-0379 group, 68.25% for the 0.1% group, and 71.61% for the 0.5% group, compared with 9.95% for the placebo group. Six adverse events were reported in four patients, of which one occurred in the placebo group, and causal relationships to study drugs were denied for all six events. Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective.

UR - http://www.scopus.com/inward/record.url?scp=85050824137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050824137&partnerID=8YFLogxK

U2 - 10.1038/s41514-018-0021-7

DO - 10.1038/s41514-018-0021-7

M3 - Article

VL - 4

JO - npj Aging and Mechanisms of Disease

JF - npj Aging and Mechanisms of Disease

SN - 2056-3973

IS - 1

M1 - 2

ER -